Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.

ABSTRACT: The addition of adjuvant chemotherapy to hormonal therapy is recommended for patients with estrogen receptor-positive (ER+), node-positive (N+) early breast cancer (EBC). Some of these patients, however, are not likely to benefit from treatment and may, therefore, be overtreated while also incurring unnecessary treatment-related adverse events and health care costs. The 21-gene Recurrence Score assay has been clinically validated and recommended for use in patients with ER+, node-negative (N0) EBC to assess the 10-year risk of distant disease recurrence and predict the likelihood of response to adjuvant chemotherapy. A growing body of evidence from several large phase III clinical trials reports similar findings in patients with ER+, N+ EBC. A systematic review of published literature from

SUBMITTER: Brufsky AM 

PROVIDER: S-EPMC4162320 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature